Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUDT15/TPMT Genotype-Guided 6-MP Dosing in Childhood ALL
NCT07462299Not yet recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Feb 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of mercaptopurine in acute lymphoblastic leukemia (ALL), sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoint: Cumulative Incidence of Grade 3 or Higher Neutropenia at 12 months. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
mercaptopurine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07462299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07462299.